How does Medtronic (MDT) make money?

Medtronic (MDT) generates revenue primarily from Cardiac and Vascular Group, which accounted for 38.5% of total revenue in TTM through Q2 2026. The company reported $36.36B in revenue and converted 13.2% of it into net profit, equivalent to roughly $4.80B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Medtronic (MDT)?

Medtronic (MDT) reported a gross profit margin of 65% in TTM through Q2 2026, equivalent to $23.64B in gross profit on $36.36B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Medtronic (MDT)?

Medtronic (MDT) reported an operating profit margin of 17.8% in TTM through Q2 2026, equivalent to $6.47B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Medtronic (MDT)?

Medtronic (MDT) reported a net profit margin of 13.2% in TTM through Q2 2026, equivalent to $4.80B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Medtronic (MDT) profitable?

Yes. Medtronic (MDT) reported $4.80B in net income for TTM through Q2 2026, with a net profit margin of 13.2%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Medtronic (MDT) invest in research and development?

Medtronic (MDT) invested $2.87B in research and development during TTM through Q2 2026, roughly 7.9% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Medtronic (MDT) spend on capital expenditures?

Medtronic (MDT) spent $1.90B on capital expenditures (CapEx) during TTM through Q2 2026, roughly 5.2% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Medtronic (MDT) generate?

Medtronic (MDT) generated $5.43B in free cash flow during TTM through Q2 2026, a free-cash-flow margin of 14.9%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Medtronic (MDT)?

Medtronic (MDT) had an effective tax rate of 21.2% in TTM through Q2 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Medtronic (MDT)?

Medtronic (MDT) reports revenue across 4 reportable product segments, led by Cardiac and Vascular Group at 38.5% of total revenue in TTM through Q2 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How Medtronic Makes Money: 2026 Visual Revenue Map

Medtronic (MDT) Income Statement Flow — TTM through Q2 2026

Calculated from the four most recent reported quarters, ending April 24, 2026 (reported June 3, 2026).

Medtronic discloses geographic revenue only in annual filings. to view the full breakdown.

Medtronic (MDT) Revenue by Product Segment — TTM through Q2 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Medtronic (MDT) in TTM through Q2 2026.
Segment	Revenue (USD)	% of total
Cardiac and Vascular Group	$14.02B	38.5%
Neuroscience Group	$10.34B	28.4%
Medical Surgical	$8.85B	24.3%
Diabetes Group	$3.15B	8.7%
Total	$36.36B	100%

Cardiac and Vascular Group$14.02B
Neuroscience Group$10.34B
Medical Surgical$8.85B
Diabetes Group$3.15B
Total$36.36B

Revenue Breakdown — TTM through Q2 2026

In TTM through Q2 2026, Medtronic (MDT) reports revenue across 4 operating segments; the largest segment was Cardiac and Vascular Group at 38.5%, followed by Neuroscience Group (28.4%) and Medical Surgical (24.3%).

Frequently asked questions

Data & methodology

Medtronic (MDT) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation